VOICED : AstraZeneca sufre revés en desarrollo de tratamiento anticovid

AstraZeneca announced a setback in their COVID-19 treatment development, as their antibody procedure failed to prevent symptomatic cases in a phase 3 trial. The trial involved 1,121 unvaccinated adults exposed to the virus, showing only a 33% reduction in symptomatic risk. Despite this, research continues for pre-exposure and severe cases. Concurrently, AstraZeneca faces challenges with their vaccine, suspended in some European countries due to blood-related issues.

What was the primary goal of AstraZeneca's antibody procedure for COVID-19?

• To treat severe COVID-19 cases

• To cure COVID-19 completely

• To prevent symptomatic COVID-19 after exposure

• To develop a vaccine

How effective was the treatment in reducing the risk of symptomatic COVID-19?

• 50%

• 90%

• 75%

• 33%

How many participants were involved in the phase 3 trials of AstraZeneca's treatment?

• 500

• 1,121

• 2,000

• 750

In which phase of development was AstraZeneca's COVID-19 treatment when the setback occurred?

• Phase 2

• Phase 1

• Phase 4

• Phase 3

What issue led to the suspension of AstraZeneca's vaccine in some European countries?

• Lack of efficacy

• Storage difficulties

• Blood clot problems

• High cost